Otonomy names new CMO
This article was originally published in Scrip
Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for disorders of the inner and middle ear, has named Dr Dean Hakanson chief medical officer. Dr Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline. He joins Otonomy from Novartis, where he was most recently vice-president and head of health economics and outcomes research (HE&OR) for US medical and drug regulatory affairs.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.